Home > Insider Trading > Filing (0001144204-15-005703)

Filing Details

Accession Number:: 0001144204-15-005703
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-02-03 21:01:10
Reporting Period:: 2015-01-30

Filing Date:: 2015-02-03
Accepted Time:: 2015-02-03 21:01:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1571320	Paul Daniel Regan	C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-01-30	9,847	$37.69	11,111	No	4	M	Direct
Common Stock	Disposition	2015-01-30	6,847	$200.07	4,264	No	4	S	Direct
Common Stock	Disposition	2015-01-30	1,207	$201.50	3,057	No	4	S	Direct
Common Stock	Disposition	2015-01-30	793	$202.49	2,264	No	4	S	Direct
Common Stock	Disposition	2015-01-30	800	$205.87	1,464	No	4	S	Direct
Common Stock	Disposition	2015-01-30	200	$208.08	1,264	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2015-01-30	9,847	$0.00	9,847	$37.69

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
92,028		2023-03-04	No	4	M	Direct

Footnotes

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 14, 2014.
The remaining shares underlying this option vest on a pro rata monthly basis through March 4, 2017, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
This transaction was executed in multiple trades at prices ranging from $200.0000 to $200.8100. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $201.0100 to $202.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $202.0100 to $203.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $205.5000 to $206.2450. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.